PAT 202: Week 1-4 Pharmacotherapy Exam
Questions and Answers
Save
Terms in this set (100)
Ticagrelor Antiplatelets
Ticagrelor indications for - reduces risk of thromboembolic events in ACS
use - with PCI, reduces risk of stent thrombosis
Ticagrelor mechanism of - blocks ADP receptors on platelets → prevents signal
action and platelet activation ⭢ ↓platelet aggregation
TICAGRELOR DESIRED ↓ cardiovascular death, MI and stroke
EFFECTS
- bleeding (can be serious/fatal)
Ticagrelor adverse effects
- dyspnea
Cyclooxygenase (COX) Inhibitors
Acetylsalicylic Acid
classification
Also is a = Antiplatelet / NSAID
, - antiplatelet (unique to this NSAID) - - significant
anticoagulant activity
- secondary prevention of vascular events - risk
reduction of recurrent vascular events (thrombosis) in
those with hx of ACS, ischemic stroke, peripheral
vascular disease
- mild to moderate pain & inflammation, fever
Acetylsalicylic Acid
Indication for use
PAT201
- TIAs, ischemic stroke, acute coronary syndrome
(ACS), secondary prevention of vascular events
- Recall: also used for its
- analgesic
- anti-inflammatory
- antipyretic properties
inhibits cyclooxygenase (COX) enzyme pathway
preventing production of prostaglandin & synthesis of
Acetylsalicylic Acid thromboxane A2
Mechanism of Action
- COX irreversibly inhibited for lifespan of platelet (7-
10 days)
inhibits platelet aggregation (effect on - platelets
Acetylsalicylic Acid
almost immediate)
desired effect
- secondary prevention of thrombotic events
, - gastric discomfort
- bleeding
- ↑ clotting time
- salicylism (can occur with high dosing) - tinnitus,
dizziness, headaches, sweating
Acetylsalicylic Acid
adverse effect
PAT201
- GI bleeds
- bruising
- N/V
- Reye's syndrome (children)
Thrombolytics: Tissue Plasminogen Activator (tPA)
Alteplase (tPA)
For maximum effectiveness:
classification
Must be given within 6 hours of the onset of
symptoms of MI and within 3 hours of thrombotic CVA
Alteplase indication for - MI and CVA related to clots (thrombotic)
use - off-label use: restore IV catheter patency
- identical to human tPA enzyme
Alteplase mechanism of - mimics body's process of clot destruction -
action *converts plasminogen to plasmin* (enzyme that
breaks down fibrin in clot) → dissolves thrombi
PAT201
**re-establishes bld flow to prevent further damage
Alteplase desired effect - re-establishes bld flow to blood-starved tissues
- limits or prevents cell death
- causes clots to dissolve
- coronary artery opens allowing perfusion of
myocardium
Questions and Answers
Save
Terms in this set (100)
Ticagrelor Antiplatelets
Ticagrelor indications for - reduces risk of thromboembolic events in ACS
use - with PCI, reduces risk of stent thrombosis
Ticagrelor mechanism of - blocks ADP receptors on platelets → prevents signal
action and platelet activation ⭢ ↓platelet aggregation
TICAGRELOR DESIRED ↓ cardiovascular death, MI and stroke
EFFECTS
- bleeding (can be serious/fatal)
Ticagrelor adverse effects
- dyspnea
Cyclooxygenase (COX) Inhibitors
Acetylsalicylic Acid
classification
Also is a = Antiplatelet / NSAID
, - antiplatelet (unique to this NSAID) - - significant
anticoagulant activity
- secondary prevention of vascular events - risk
reduction of recurrent vascular events (thrombosis) in
those with hx of ACS, ischemic stroke, peripheral
vascular disease
- mild to moderate pain & inflammation, fever
Acetylsalicylic Acid
Indication for use
PAT201
- TIAs, ischemic stroke, acute coronary syndrome
(ACS), secondary prevention of vascular events
- Recall: also used for its
- analgesic
- anti-inflammatory
- antipyretic properties
inhibits cyclooxygenase (COX) enzyme pathway
preventing production of prostaglandin & synthesis of
Acetylsalicylic Acid thromboxane A2
Mechanism of Action
- COX irreversibly inhibited for lifespan of platelet (7-
10 days)
inhibits platelet aggregation (effect on - platelets
Acetylsalicylic Acid
almost immediate)
desired effect
- secondary prevention of thrombotic events
, - gastric discomfort
- bleeding
- ↑ clotting time
- salicylism (can occur with high dosing) - tinnitus,
dizziness, headaches, sweating
Acetylsalicylic Acid
adverse effect
PAT201
- GI bleeds
- bruising
- N/V
- Reye's syndrome (children)
Thrombolytics: Tissue Plasminogen Activator (tPA)
Alteplase (tPA)
For maximum effectiveness:
classification
Must be given within 6 hours of the onset of
symptoms of MI and within 3 hours of thrombotic CVA
Alteplase indication for - MI and CVA related to clots (thrombotic)
use - off-label use: restore IV catheter patency
- identical to human tPA enzyme
Alteplase mechanism of - mimics body's process of clot destruction -
action *converts plasminogen to plasmin* (enzyme that
breaks down fibrin in clot) → dissolves thrombi
PAT201
**re-establishes bld flow to prevent further damage
Alteplase desired effect - re-establishes bld flow to blood-starved tissues
- limits or prevents cell death
- causes clots to dissolve
- coronary artery opens allowing perfusion of
myocardium
